Trial Profile

An Open-Label, Multicenter, Phase 1 Study of IGM-2644 in Participants With Relapsed and/or Refractory Multiple Myeloma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 05 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IGM-2644 (Primary)
Indications Multiple myeloma
Focus Adverse reactions; First in man
Sponsors IGM Biosciences

Most Recent Events

01 Aug 2024 According to Clinicaltrial.gov record this trial was terminated due to Company Decision
01 Aug 2024 Status changed from recruiting to discontinued.
12 May 2023 Status changed from planning to recruiting, according to an IGM Biosciences media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com